Recent Updates — ARTV

Artiva Biotherapeutics announced the discontinuation of its lead candidate AlloNK (AB-101) following updated clinical data showing insufficient durability of response and two Grade 5 safety events, including one likely linked to fludarabine toxicity. The company is reducing its workforce by approximately 94% to preserve capital while it explores strategic alternatives such as a merger, asset sale, or liquidation. Preliminary cash, cash equivalents, and investments stood at $319.1 million as of September 30, 2026. Artiva Biotherapeutics is a clinical-stage biotechnology company developing allogeneic natural killer cell therapies for autoimmune diseases.

Artiva Biotherapeutics reported a net loss of $25.0 million for the quarter ended June 30, 2026, compared to $21.3 million in the prior year period. The company holds $349.4 million in cash and investments, sufficient to fund operations into 2029. Artiva announced it will initiate a Phase 3 registrational trial for AlloNK plus rituximab in approximately 150 refractory rheumatoid arthritis patients in the second half of 2026, following FDA RMAT designation. The firm also appointed Diego Miralles as president and head of R&D. Artiva Biotherapeutics is a clinical-stage biotechnology company developing cell therapies for autoimmune diseases.